Literature DB >> 11440281

Current options for the prevention and treatment of migraine.

J U Adelman1, R D Adelman.   

Abstract

BACKGROUND: Migraine is a common condition affecting approximately 18% of women and 6% of men in the United States. The goals of managing migraine are 2-fold: to prevent attacks from occurring and to effectively and rapidly end them when they do occur.
OBJECTIVE: This article reviews the acute and prophylactic treatment of migraine.
METHODS: Information for inclusion in this review was identified through a search of MEDLINE from 1995 to the present. Search terms included migraine, acute treatment, prophylactic treatment, preventive treatment, and individual drug names.
RESULTS: Preventive measures for migraine include lifestyle changes (eg, avoiding migraine triggers and maintaining regular sleep, eating, and work habits) and drug therapy. Beta-blockers, calcium channel blockers, tricyclic antidepressants, and anticonvulsants are among the more common drug classes used for migraine prophylaxis, but preventive therapy must be individualized, taking into account efficacy, potential adverse effects, co-existing medical conditions, and drug costs. Many medications are available for the acute treatment of migraine, including over-the-counter analgesics and prescription drugs. Of the latter, the 5-hydroxytryptamine(1B/1D)-receptor agonists, or triptans, are the most recently introduced class. Each of the 4 available triptans (sumatriptan, zolmitriptan, naratriptan, and rizatriptan) is effective in ending a migraine attack, but comparative trials have shown differences between individual drugs in the time to pain relief and the percentage of patients who obtain pain relief.
CONCLUSIONS: Medications to prevent or reduce the frequency of migraine tend to be less specific and effective than medications for the acute treatment of migraine. As a class, triptans are generally well tolerated and may be considered drugs of choice for the acute treatment of moderate to severe migraine.

Entities:  

Mesh:

Year:  2001        PMID: 11440281     DOI: 10.1016/s0149-2918(01)80069-2

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  7 in total

1.  Adverse reactions related to drugs for headache treatment: clinical impact.

Authors:  Anna Ferrari; Alessandra Ottani; Alfio Bertolini; Arrigo Francesco Giuseppe Cicero; Ciro Pio Rosario Coccia; Sheila Leone; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

Review 2.  Rizatriptan: an update of its use in the management of migraine.

Authors:  Keri Wellington; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  The pharmacological management of migraine, part 1: overview and abortive therapy.

Authors:  George Demaagd
Journal:  P T       Date:  2008-07

4.  BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.

Authors:  K A Maubach; R J Davis; D E Clark; G Fenton; P M Lockey; K L Clark; A W Oxford; R M Hagan; C Routledge; R A Coleman
Journal:  Br J Pharmacol       Date:  2009-01-19       Impact factor: 8.739

5.  Migraine and its relationship with dietary habits in women.

Authors:  Fatemeh Nazari; Maryam Eghbali
Journal:  Iran J Nurs Midwifery Res       Date:  2012-02

6.  Psychiatric Comorbidities and Environmental Triggers in Patients with Chronic Daily Headache: A Lifestyle Study.

Authors:  Fakhrudin Faizi; Abbas Tavallaee; Aboulfazl Rahimi; Masoud Saghafinia
Journal:  Iran J Psychiatry       Date:  2017-01

7.  Acute migraine: Current treatment and emerging therapies.

Authors:  Arun A Kalra; Debra Elliott
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.